NCT00002157已完成不适用
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting in order to support Celgene's pivotal placebo-controlled study.
详细描述
Patients are randomized to receive thalidomide at 1 of 2 doses for 12 weeks initially, with response assessed at weeks 2, 4, 8, and 12. Patients failing the low dose will be eligible to increase the dose to the higher dose. Treatment may continue indefinitely. After 12 weeks, patients continuing treatment are evaluated every 2 months for up to 6 additional months, then every 6 months thereafter.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug TreatmentHIV InfectionsNCT00006152National Institute of Allergy and Infectious Diseases (NIAID)42
Unknown
4 期
Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve SubjectsHIV PositiveNCT02404233Therapeutic Concepts30
已完成
1 期
Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/EmtricitabineHIV InfectionsNCT03836729ViiV Healthcare16
已完成
2 期
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral RegimensHIV InfectionsNCT00052117Pfizer300
已完成
4 期
A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL StudyHIV InfectionsNCT00192634Kirby Institute357